Allogeneic retrovirally transduced, IL-2- and IFN-γ-secreting cancer cell vaccine in patients with hormone refractory prostate cancer—a phase I clinical trial-Reference-Cited by-同舟云学术

Allogeneic retrovirally transduced, IL-2- and IFN-γ-secreting cancer cell vaccine in patients with hormone refractory prostate cancer—a phase I clinical trial

Published:2007 Issue:7 Volume:9 Page:547-560
ISSN:1099-498X
Container-title:The Journal of Gene Medicine
language:en
Short-container-title:J. Gene Med.

Author:

Brill T. H.,Kübler H. R.,Randenborgh H. v.,Fend F.,Pohla H.,Breul J.,Hartung R.,Paul R.,Schendel D. J.,Gansbacher B.

Publisher

Wiley

Subject

Genetics (clinical),Drug Discovery,Genetics,Molecular Biology,Molecular Medicine

Reference94 articles.

1. Cancer Statistics, 2006

2. Hormone refractory prostate cancer: Management and advances

3. Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer

4. Cancer Immunotherapy With Peptide-Based Vaccines: What Have We Achieved? Where Are We Going?

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential of Personalized Dendritic Cell-Based Immunohybridoma Vaccines to Treat Prostate Cancer;Life;2023-07-01

2. Changing Landscape of Cancer Vaccines—Novel Proteomics Platform for New Antigen Compositions;International Journal of Molecular Sciences;2022-04-15

3. Chronic prostatitis/chronic pelvic pain syndrome and prostate cancer: study of immune cells and cytokines;Fundamental & Clinical Pharmacology;2019-11-12

4. The untold story of IFN-γ in cancer biology;Cytokine & Growth Factor Reviews;2016-10

5. Synergistic immunologic targets for the treatment of prostate cancer;Experimental Biology and Medicine;2016-07-28